Endotoxaemia resulting from decreased serotonin tranporter (5-HTT) function: A reciprocal risk factor for depression and insulin resistance?

Behavioural Brain Research

Volumn 276, Issue , 2015, Pages 111-117

  Pomytkin, Igor A ^a   Cline, Brandon H ^b   Anthony, Daniel C ^c   Steinbusch, Harry W ^d   Lesch, Klaus Peter ^d,e   Strekalova, Tatyana ^d,f,g  

^a Buddha Biopharma Oy   (Finland)

^b CENTRE DES SCIENCES DU GOÛT ET DE L ALIMENTATION   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^g INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

5 HT; Antidepressant; Depression; Endotoxemia; Inflammation; Insulin resistance

Indexed keywords

ENDOTOXIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TOLL LIKE RECEPTOR 4; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT; SEROTONIN 3 RECEPTOR;

CARBOHYDRATE DIET; DEPRESSION; DIABETES MELLITUS; DISEASE MODEL; ENDOTOXEMIA; FAT INTAKE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSION; DIABETES MELLITUS, TYPE 2; ENDOTOXEMIA; HUMANS; INFLAMMATION; INSULIN RESISTANCE; RECEPTOR, INSULIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84908569975     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.04.049     Document Type: Review

References (112)

1. Kan C., Silva N., Golden S.H., Rajala U., Timonen M., Stahl D., et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 2013, 36:480-489.
2. Cline B.H., Steinbusch H.W., Malin D., Revishchin A.V., Pavlova G.V., Cespuglio R., et al. The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2. BMC Neurosci 2012, 13:110.
3. Pyykkonen A.J., Raikkonen K., Tuomi T., Eriksson J.G., Groop L., Isomaa B. Depressive symptoms, antidepressant medication use, and insulin resistance: the PPP-Botnia Study. Diabetes Care 2011, 34:2545-2547.
4. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
5. Egede L.E., Ellis C. Diabetes and depression: global perspectives. Diabetes Res Clin Pract 2010, 87:302-312.
6. Atlantis E., Baker M. Obesity effects on depression: systematic review of epidemiological studies. Int J Obes 2008, 32:881-891.
7. de Wit L., Luppino F., van Straten A., Penninx B., Zitman F., Cuijpers P. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 2010, 178:230-235.
8. Luppino F.S., de Wit L.M., Bouvy P.F., Stijnen T., Cuijpers P., Penninx B.W., et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010, 67:220-229.
9. Pan A., Sun Q., Czernichow S., Kivimaki M., Okereke O.I., Lucas M., et al. Bidirectional association between depression and obesity in middle-aged and older women. Int J Obes 2012, 36:595-602.
10. Zimmet P., Dowse G., La Porte R., Finch C., Moy C. Epidemiology - Its Contribution to Understanding of the Etiology, Pathogenesis, and Prevention of Diabetes Mellitus. Search instead for amedical odyssey 1971, 87-89. USV Pharmaceutical Corp., Tuckahoe, N.Y.: USV Willis Tuckahoe, N.Y. A.R. Gennaro (Ed.).
11. Palinkas L.A., Barrett-Connor E., Wingard D.L. Type 2 diabetes and depressive symptoms in older adults: a population-based study. Diabet Med 1991, 8:532-539. (a journal of the British Diabetic Association).
12. Talbot F., Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link. Diabetes Care 2000, 23:1556-1562.
13. Loktionov A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). J Nutr Biochem 2003, 14:426-451.
14. Hallschmid M., Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders. Diabetologia 2009, 52:2264-2269.
15. Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabetic Med 2006, 23:445-448. (a journal of the British Diabetic Association).
16. Roy T., Lloyd C.E. Epidemiology of depression and diabetes: a systematic review. J Affect Disord 2012, 142(Suppl):S8-S21.
17. Anderson R.J., Freedland K.E., Clouse R.E., Lustman P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001, 24:1069-1078.
18. Ali S., Stone M.A., Peters J.L., Davies M.J., Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabetic Med 2006, 23:1165-1173. (a journal of the British Diabetic Association).
19. Demakakos P., Pierce M.B., Hardy R. Depressive symptoms and risk of type 2 diabetes in a national sample of middle-aged and older adults: the English longitudinal study of aging. Diabetes Care 2010, 33:792-797.
20. Lin E.H., Rutter C.M., Katon W., Heckbert S.R., Ciechanowski P., Oliver M.M., et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care 2010, 33:264-269.
21. Williams L.H., Rutter C.M., Katon W.J., Reiber G.E., Ciechanowski P., Heckbert S.R., et al. Depression and incident diabetic foot ulcers: a prospective cohort study. Am J Med 2010, 123:748-754. e3.
22. Katon W.J., Rutter C., Simon G., Lin E.H., Ludman E., Ciechanowski P., et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005, 28:2668-2672.
23. van Dooren F.E., Nefs G., Schram M.T., Verhey F.R., Denollet J., Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 2013, 8:e57058.
24. Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008, 31:2383-2390.
25. Campayo A., de Jonge P., Roy J.F., Saz P., de la Camara C., Quintanilla M.A., et al. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry 2010, 167:580-588.
26. Rotella F., Mannucci E. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry 2013, 74:31-37.
27. Nouwen A., Winkley K., Twisk J., Lloyd C.E., Peyrot M., Ismail K., et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010, 53:2480-2486.
28. Rotella F., Mannucci E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res Clin Pract 2013, 99:98-104.
29. Chen P.C., Chan Y.T., Chen H.F., Ko M.C., Li C.Y. Population-based cohort analyses of the bidirectional relationship between type 2 diabetes and depression. Diabetes Care 2013, 36:376-382.
30. Vancampfort D., Correll C.U., Wampers M., Sienaert P., Mitchell A.J., De Herdt A., et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2013, 1-12.
31. Pan A., Keum N., Okereke O.I., Sun Q., Kivimaki M., Rubin R.R., et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012, 35:1171-1180.
32. Rubin R.R., Ma Y., Marrero D.G., Peyrot M., Barrett-Connor E.L., Kahn S.E., et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008, 31:420-426.
33. Rubin R.R., Ma Y., Peyrot M., Marrero D.G., Price D.W., Barrett-Connor E., et al. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 2010, 33:2549-2551.
34. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009, 166:591-598.
35. Pan A., Sun Q., Okereke O.I., Rexrode K.M., Rubin R.R., Lucas M., et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 2012, 55:63-72.
36. Barnard K., Peveler R.C., Holt R.I. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care 2013, 36:3337-3345.
37. Kivimaki M., Hamer M., Batty G.D., Geddes J.R., Tabak A.G., Pentti J., et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010, 33:2611-2616.
38. Kivimaki M., Batty G.D., Jokela M., Ebmeier K.P., Vahtera J., Virtanen M., et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association. Biol Psychiatry 2011, 70:978-984.
39. Caughey G.E., Preiss A.K., Vitry A.I., Gilbert A.L., Ryan P., Shakib S., et al. Does antidepressant medication use affect persistence with diabetes medicines. Pharmacoepidemiol Drug Saf 2013, 22:615-622.
40. Kornegay C.J., Vasilakis-Scaramozza C., Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002, 63:758-762.
41. Koro C.E., Fedder D.O., Gilbert J.L., Weiss S.S., Magder L.S., Kreyenbuhl J., et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ: Br Med J 2002, 325:243.
42. Lambert B.L., Chou C.H., Chang K.Y., Tafesse E., Carson W. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 2005, 14:417-425.
43. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002, 159:561-566.
44. Yood M.U., DeLorenze G., Quesenberry C.P., Oliveria S.A., Tsai A.L., Willey V.J., et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009, 18:791-799.
45. Ojha S.K., Nandave M., Sharma C. Effect of buspirone: an anxiolytic drug on blood glucose in humans. Indian J Clin Biochem: IJCB 2006, 21:58-62.
46. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008, 29:287-291.
47. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
48. Ghanim H., Abuaysheh S., Sia C.L., Korzeniewski K., Chaudhuri A., Fernandez-Real J.M., et al. Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal implications for insulin resistance. Diabetes Care 2009, 32:2281-2287.
49. Campbell S.J., Deacon R.M., Jiang Y., Ferrari C., Pitossi F.J., Anthony D.C. Overexpression of IL-1β by adenoviral-mediated gene transfer in the rat brain causes a prolonged hepatic chemokine response, axonal injury and the suppression of spontaneous behaviour. Neurobiol Dis 2007, 27:151-163.
50. Couch Y., Anthony D.C., Dolgov O., Revischin A., Festoff B., Santos A.I., et al. Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain Behav Immun 2013, 29:136-146.
51. Dasu M.R., Devaraj S., Park S., Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010, 33:861-868.
52. Liang H., Hussey S.E., Sanchez-Avila A., Tantiwong P., Musi N. Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One 2013, 8:e63983.
53. Creely S.J., McTernan P.G., Kusminski C.M., Da Silva N., Khanolkar M., Evans M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E740-E747.
54. Baganz N.L., Blakely R.D. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci 2013, 4:48-63.
55. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131. (official publication of the American College of Neuropsychopharmacology).
56. Lowry C.A., Hollis J.H., de Vries A., Pan B., Brunet L.R., Hunt J.R., et al. Identification of an immune-responsive mesolimbocortical serotonergic system: potential role in regulation of emotional behavior. Neuroscience 2007, 146:756-772.
57. Homberg J.R., Lesch K-P. Looking on the bright side of serotonin transporter gene variation. Biol Psychiatry 2011, 69:513-519.
58. Lesch K-P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
59. Racke K., Reimann A., Schworer H., Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behav Brain Res 1996, 73:83-87.
60. Chen X., Margolis K.J., Gershon M.D., Schwartz G.J., Sze J.Y. Reduced serotonin reuptake transporter (SERT) function causes insulin resistance and hepatic steatosis independent of food intake. PLoS One 2012, 7:e32511.
61. Gershon M. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004, 20:3-14.
62. Kidd M., Modlin I.M., Gustafsson B.I., Drozdov I., Hauso O., Pfragner R. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 2008, 295:G260-G272.
63. Ni W., Thompson J.M., Northcott C.A., Lookingland K., Watts S.W. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 2004, 43:770-781.
64. Gershon M.D. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2013, 20:14.
65. Gill R.K., Pant N., Saksena S., Singla A., Nazir T.M., Vohwinkel L., et al. Function, expression, and characterization of the serotonin transporter in the native human intestine. Am J Physiol Gastrointest Liver Physiol 2008, 294:G254-G262.
66. Stunes A., Reseland J., Hauso Ö., Kidd M., Tømmerås K., Waldum H., et al. Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation. Diabetes Obes Metab 2011, 13:551-558.
67. Haub S., Kanuri G., Volynets V., Brune T., Bischoff S.C., Bergheim I. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol 2010, 298:G335-G344.
68. Yamada T., Inui A., Hayashi N., Fujimura M., Fujimiya M. Serotonin stimulates endotoxin translocation via 5-HT3 receptors in the rat ileum. Am J Physiol Gastrointest Liver Physiol 2003, 284:G782-G788.
69. Ruddell R.G., Oakley F., Hussain Z., Yeung I., Bryan-Lluka L.J., Ramm G.A., et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 2006, 169:861-876.
70. Li R.W., Yang C., Kwan Y-W., Chan S-W., Lee S.M., Leung G.P. Involvement of organic cation transporter-3 and plasma membrane monoamine transporter in serotonin uptake in human brain vascular smooth muscle cells. Front Pharmacol 2013, 4-14.
71. Nylander O., Pihl L. Luminal hypotonicity increases duodenal mucosal permeability by a mechanism involving 5-hydroxytryptamine. Acta Physiol 2006, 186:45-58.
72. Maes M., Kubera M., Leunis J.C., Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012, 141:55-62.
73. Maes M., Mihaylova I., Leunis J.C. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord 2007, 99:237-240.
74. Mössner R., Schmitt A., Hennig T., Benninghoff J., Gerlach M., Riederer P., et al. Quantitation of 5HT3 receptors in forebrain of serotonin transporter deficient mice. J Neural Transm 2004, 111:27-35.
75. Brun P., Castagliuolo I., Di Leo V., Buda A., Pinzani M., Palu G., et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007, 292:G518-G525.
76. Haub S., Ritze Y., Ladel I., Saum K., Hubert A., Spruss A., et al. Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. J Pharmacol Exp Ther 2011, 339:790-798.
77. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
78. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
79. Garate I., Garcia-Bueno B., Madrigal J.L., Bravo L., Berrocoso E., Caso J.R., et al. Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation 2011, 8:151.
80. Lee Y.H., Giraud J., Davis R.J., White M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003, 278:2896-2902.
81. Jarrell H., Hoffman J.B., Kaplan J.R., Berga S., Kinkead B., Wilson M.E. Polymorphisms in the serotonin reuptake transporter gene modify the consequences of social status on metabolic health in female rhesus monkeys. Physiol Behav 2008, 93:807-819.
82. Aguirre V., Uchida T., Yenush L., Davis R., White M.F. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem 2000, 275:9047-9054.
83. Karin M., Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005, 57:283-295.
84. Liang B., Moussaif M., Kuan C-J., Gargus J.J., Sze J.Y. Serotonin targets the DAF-16/FOXO signaling pathway to modulate stress responses. Cell Metab 2006, 4:429-440.
85. Bogoyevitch M.A., Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006, 70:1061-1095.
86. Dong C., Davis R.J., Flavell R.A. MAP kinases in the immune response. Annu Rev Immunol 2002, 20:55-72.
87. Huang W., Zhao Y., Zhu X., Cai Z., Wang S., Yao S., et al. Fluoxetine upregulates phosphorylated-AKT and phosphorylated-ERK1/2 proteins in neural stem cells: evidence for a crosstalk between AKT and ERK1/2 pathways. J Mol Neurosci: MN 2013, 49:244-249.
88. Mao Z., Liu L., Zhang R., Li X. Lithium reduces FoxO3a transcriptional activity by decreasing its intracellular content. Biol Psychiatry 2007, 62:1423-1430.
89. Polter A., Yang S., Zmijewska A.A., van Groen T., Paik J.H., Depinho R.A., et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 2009, 65:150-159.
90. Cowen D.S., Johnson-Farley N.N., Travkina T. 5-HT1A receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons. J Neurochem 2005, 93:910-917.
91. Hsu E.H., Lochan A.C., Cowen D.S. Activation of Akt1 by human 5-hydroxytryptamine (serotonin) 1B receptors is sensitive to inhibitors of MEK. J Pharmacol Exp Ther 2001, 298:825-832.
92. Lione A.M., Errico M., Lin S.L., Cowen D.S. Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT1B receptors in transfected BE (2)-C neuroblastoma cells is inhibited by RGS4. J Neurochem 2000, 75:934-938.
93. Gómez dPT, Velasco G., Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 2000, 347:369-373.
94. Gomez O., Sanchez-Rodriguez A., Le M., Sanchez-Caro C., Molina-Holgado F., Molina-Holgado E. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. Br J Pharmacol 2011, 163:1520-1532.
95. Johnson-Farley N.N., Travkina T., Cowen D.S. Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J Pharmacol Exp Ther 2006, 316:1062-1069.
96. Mai L., Jope R.S., Li X. BDNF-mediated signal transduction is modulated by GSK3β and mood stabilizing agents. J Neurochem 2002, 82:75-83.
97. Stroppolo A., Guinea B., Tian C., Sommer J., Ehrlich M.E. Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro. J Neurochem 2001, 79:1027-1032.
98. Zheng W.H., Kar S., Quirion R. FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling. J Neurochem 2002, 80:1049-1061.
99. Zhu W., Bijur G.N., Styles N.A., Li X. Regulation of FOXO3a by brain-derived neurotrophic factor in differentiated human SH-SY5Y neuroblastoma cells. Mol Brain Res 2004, 126:45-56.
100. Hui L., Pei D-S., Zhang Q-G., Guan Q-H., Zhang G-Y. The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation. Brain Res 2005, 1052:1-9.
101. Lee C-C., Huang C-C., Wu M-Y., Hsu K-S. Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J Biol Chem 2005, 280:18543-18550.
102. Fey D., Croucher D.R., Kolch W., Kholodenko B.N. Crosstalk and signaling switches in mitogen-activated protein kinase cascades. Front Physiol 2012, 3:355.
103. Sunayama J., Tsuruta F., Masuyama N., Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 2005, 170:295-304.
104. Karege F., Perroud N., Burkhardt S., Schwald M., Ballmann E., La Harpe R., et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3β in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007, 61:240-245.
105. Zhou W., Chen L., Yang S., Li F., Li X. Behavioral stress-induced activation of FoxO3a in the cerebral cortex of mice. Biol Psychiatry 2012, 71:583-592.
106. Wei L., Liu Y., Kaneto H., Fanburg B.L. JNK regulates serotonin-mediated proliferation and migration of pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2010, 298:L863-L869.
107. Bertrand R.L., Senadheera S., Markus I., Liu L., Howitt L., Chen H., et al. A Western diet increases serotonin availability in rat small intestine. Endocrinology 2011, 152:36-47.
108. Kim M., Cooke H.J., Javed N.H., Carey H.V., Christofi F., Raybould H.E. d-glucose releases 5-hydroxytryptamine from human BON cells as a model of enterochromaffin cells. Gastroenterology 2001, 121:1400-1406.
109. Kullmann J.S., Grigoleit J.S., Lichte P., Kobbe P., Rosenberger C., Banner C., et al. Neural response to emotional stimuli during experimental human endotoxemia. Hum Brain Mapp 2013, 34:2217-2227.
110. Consortium C-DGotPG Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013.
111. Kalueff A.V., Stewart A.M. Modeling neuropsychiatric spectra to empower translational biological psychiatry. Behav Brain Res 2014, 276:1-7.
112. Golimbet V.E., Ukraintseva S.V., Iashin A.I., Korovaitseva G.I., Shal'nova S.A., Deev A.D., et al. [Serotonin transporter gene polymorphism and factors influencing mental and physical health in aging]. Zh Nevrol Psikhiatr Im S S Korsakova 2004, 104(5):46-49.